The groundbreaking success of Sildenafil undeniably revolutionized the drug landscape, but betting in companies strongly reliant on generic versions presents a uncertain picture. Although early earnings were significant, the cessation of patents and the rise of cheaper alternatives have weakened sales. Therefore, a thorough analysis of current reve